Oxford BioMedica plc (LON:OXB) insider Andrew Heath acquired 3,312 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The stock was purchased at an average cost of GBX 673 ($8.79) per share, with a total value of £22,289.76 ($29,125.52).

Andrew Heath also recently made the following trade(s):

  • On Wednesday, February 6th, Andrew Heath sold 2,832 shares of Oxford BioMedica stock. The shares were sold at an average price of GBX 703 ($9.19), for a total transaction of £19,908.96 ($26,014.58).
  • On Monday, February 4th, Andrew Heath acquired 2,000 shares of Oxford BioMedica stock. The stock was purchased at an average cost of GBX 709 ($9.26) per share, with a total value of £14,180 ($18,528.68).

LON:OXB opened at GBX 694 ($9.07) on Wednesday. The company has a debt-to-equity ratio of 118.46, a current ratio of 2.44 and a quick ratio of 2.26. The stock has a market capitalization of $459.07 million and a price-to-earnings ratio of 63.67. Oxford BioMedica plc has a 1-year low of GBX 577 ($7.54) and a 1-year high of GBX 1,062.60 ($13.88).

Separately, Peel Hunt reissued a “buy” rating on shares of Oxford BioMedica in a research report on Tuesday, April 2nd.

COPYRIGHT VIOLATION WARNING: This news story was posted by Marea Informative and is the sole property of of Marea Informative. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.mareainformativa.com/news/2019/04/24/oxford-biomedica-plc-oxb-insider-andrew-heath-buys-3312-shares.html.

Oxford BioMedica Company Profile

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.

Recommended Story: Debt-To-Equity Ratio

Insider Buying and Selling by Quarter for Oxford BioMedica (LON:OXB)

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.